Skip to main content

Sex-Specific miRNA Differences in Liquid Biopsies from Subjects with Solid Tumors and Healthy Controls.

Tomeva E, Krammer UDB, Switzeny OJ, Haslberger AG, Hippe B

Publication: Epigenomes (2023) • Vol 7PMID: 36648863View on PubMed

Purpose

The purpose of this paper was to compare cell-free miRNAs levels and cell-free DNA (cfDNA) methylation in plasma from male and female patients with solid tumors and healthy controls.

Conclusion

Levels of miR-17-5p and miR-26b-5p were lower in plasma collected from healthy females than males after correction for patient body mass index (BMI) and age. Plasma from female cancer patients had lower levels of miR-126-3p, miR-21-5p, miR -92a-3p, and miR-183-5p than plasma from male cancer patients after correction for cancer type, cancer stage, patient age, and patient BMI. Among patients with colorectal cancer, levels of miR-186-5p, miR-22-3p, miR-22-5p, miR-25-3p, mIR-92a-3p, and miR-16-5p were significantly higher in plasma from male than female patients after correction for cancer stage, patient BMI, and patient age. In patients with stomach cancer, miR-133a-3p and miR-22-5p levels were lower in plasma from men than women after correction for cancer stage, patient BMI, and patient age. None of the miRNAs examined were differentially expressed when the plasma of male and female patients with pancreatic cancer were compared. Levels of miR-27a-3p were weakly correlated with cancer stage in female patients, but not male patients; although, levels of miR-17-5p and miR-20a-5p were negatively and weakly to modestly correlated with cancer stage in plasma from male patients, but not female patients.

Although a difference in stratifin (SFN) cfDNA methylation was observed between plasma from males and females with cancer (all types combined), the difference was not significant after correction for cancer type, cancer stage, patient BMI, and patient age and no sex-specific difference was observed in healthy patients, or patients with colorectal, pancreatic or stomach cancer.

Studies (1)

Purpose

The purpose of this paper was to compare cell-free miRNAs levels and cell-free DNA (cfDNA) methylation in plasma collected from male and female patients with solid tumors and healthy controls. Blood was obtained from 15 healthy volunteers (8 female and 7 male) and 128 patients with solid tumors (48 female and 80 male). Patient tumors included colorectal (14 females and 14 males), stomach (8 females and 15 males), pancreas (6 females and 6 males), and other types (48 females and 80 males with liver bladder, brain, or lung tumors).  Plasma was obtained by double centrifugation (speed and duration not specified). Cell-free DNA was isolated using the MagMAX Cell-Free DNA Isolation Kit and stored at -20°C. Methylated and unmethylated cfDNA were separated using the MethylMiner Methylated DNA Enrichment Kit and methylation of the promoter of SEPT9, MLH1, MGMT, GATA5, GSTP1, SFN, MDR1, VIM, SHOX2, ALKBH3, APC, and RASSF1A was assayed by real-time PCR. Cell-free miRNA was extracted from plasma using MagMAX mirVana Total RNA Kit and 48 miRNAs were quantified by real-time PCR. The mean age of female patients was 64.0 versus 65.3 years for male patients. The mean BMI was 24.1 for female patients and 25.5 for male patients.  

Summary of Findings

Levels of miR-17-5p and miR-26b-5p were lower in plasma from healthy females than males (P=0.027 and P=0.036, respectively) and significance was retained after correction for patient BMI and age (P=0.027 and P=0.011). Plasma from female cancer patients had lower levels of miR-126-3p, miR-21-5p, miR-92a-3p, miR-183-5p, and miR-16-5p than plasma from male cancer patients (P<0.05, all). Importantly, differences in levels of miR-126-3p, miR-21-5p, miR -92a-3p, and miR-183-5p (but not miR -16-5p) were observed after correction for cancer type, cancer stage, patient age, and patient BMI (P=0.0017, P=0.006, P=0.01, and P=0.015, respectively). Among patients with colorectal cancer, levels of miR-133a-3p, miR-186-5p, miR-195-5p, miR-21-5p, miR-210-3p, miR22-3p, miR-22-5p, miR-25-3p, miR34a-5p, miR-92a-3p, and miR-16-5p were significantly higher in specimens from male than female patients; however, after correction for cancer stage, patient BMI, and patient age, only differences in miR-186-5p, miR-22-3p, miR-22-5p, miR-25-3p, mIR-92a-3p, and miR-16-5p were significant (P=0.003, P=0.039, P=0.038, P=0.003, P=0.007 and P=0.021, respectively). In patients with stomach cancer, miR-133a-3p and miR-22-5p levels were lower in plasma from men than women (P=0.019 and P=0.02, respectively) and significance remained after correction for cancer stage, patient BMI, and patient age (P=0.037 and P=0.042, respectively). None of the miRNAs evaluated were differentially expressed in the plasma of male and female patients with pancreatic cancer. Levels of miR-27a-3p were positively correlated with cancer stage in female patients (ρ=0.309, P=0.024), but not male patients. Conversely, miR-17-5p and miR-20a-5p were negatively correlated with cancer stage in plasma from male patients (ρ=-0.22, P = 0.047 and ρ= -0.239, P = 0.028, respectively), but not female patients.

Although differences in Stratifin cfDNA methylation were observed when plasma from males and females with cancer (all types combined) were compared, the difference was not significant after correction for cancer type, cancer stage, patient BMI, and patient age and no sex-specific difference was observed in healthy patients, or patients with colorectal, pancreatic or stomach cancer.

  • Biospecimens

    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
    NeoplasticCarcinoma
  • Platforms

    DNAReal-time qPCR
    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Colorectal tumor
    Healthy
    Other solid tumor (liver bladder, brain, and lung tumors)
    Pancreatic tumor
    Stomach tumor
    PreaquisitionPatient gender
    Female
    Male